Epitalon, TB-500, and NAD+ reference standards

Catalog reality before article angle

The prompt requested Epitalon, Thymosin Beta 4, and Thymalin. The verified 41-product catalog contains <a href="/product/cp-040">CP-040 Epitalon</a>, <a href="/product/cp-031">CP-031 TB-500</a>, <a href="/product/cp-041">CP-041 NAD+ lyophilized</a>, and <a href="/product/cp-045">CP-045 Thymosin Alpha-1</a>. It does not contain a Thymalin SKU. The safest article therefore keeps the long-form topic in the longevity and thymic-reference cluster, links only verified CP codes, and flags Thymalin for human catalog review.

This is not a failure of the article; it is the correct no-fabrication response. The article can still close major orphaned-PDP gaps by giving CP-040, CP-031, and CP-041 a shared reference-standard guide. It should not invent a CP code for Thymalin. It should also avoid implying that NAD+ is a peptide. NAD+ is a coenzyme reference lyophilizate, so it belongs in the article as a chemistry contrast rather than as another peptide in the same structural family.

Epitalon: tetrapeptide mass and sequence simplicity

Epitalon is cataloged at 390.4 Da as a tetrapeptide reference standard. A short chain creates a concise COA problem: confirm the sequence-derived mass, confirm purity, check water content, and verify the lot number. Small peptides can be deceptively easy to over-summarise. The mass difference between deletion products and the target species is large in percentage terms, and salt or water accounting can shift the practical mass per vial.

The article should therefore discuss Epitalon as a defined tetrapeptide, not as a broad category label. HPLC-MS verified identity is the core method. Reversed-phase HPLC confirms main-peak dominance. Karl Fischer and residual-solvent methods complete the release file. The content should stay framed for in-vitro research and for in-vitro research use only and not for human or veterinary use.

TB-500: thymosin beta-4 sequence context

TB-500 is cataloged as a thymosin beta-4 fragment reference lyophilizate at 4963.4 Da. It is much larger than Epitalon, so the analytical profile changes completely. The full-length thymosin beta-4 sequence class is associated with actin-binding motifs, including the LKKTETQ region discussed in the literature. A COA reviewer should therefore check molecular weight, sequence assignment, terminal state, HPLC profile, and storage condition rather than treating TB-500 as a generic repair-family label.

The longer chain also creates more impurity opportunities: deletion sequences, oxidation or deamidation where applicable, broader peak shape, and method-dependent recovery. The article can link to <a href="/research-guide/ghk-cu-copper-peptide-complexes">GHK-Cu copper peptide complex chemistry</a> and <a href="/research-guide/ll37-magainin-cationic-peptides">LL-37 and Magainin II cationic peptide chemistry</a> because both pages show how sequence features change analytical behaviour. Those are structural links, not shared-outcome claims.

NAD+: a coenzyme reference lyophilizate, not a peptide

CP-041 NAD+ belongs in the longevity category but should not be described as a peptide. It is a coenzyme reference lyophilizate with a catalog mass of 663.4 Da. Its COA questions overlap with peptides only at the quality-system level: identity, purity, water content, residual solvents, lot traceability, and storage. The structural chemistry differs because there is no peptide bond sequence to verify.

This contrast is useful for search and procurement. A buyer looking through the longevity group can see why Epitalon, TB-500, and NAD+ need different analytical language. Epitalon is a tetrapeptide. TB-500 is a larger thymosin beta-4-class peptide. NAD+ is a nucleotide-derived coenzyme material. One article can connect them as reference standards while keeping their chemistry separate.

Thymalin and Thymosin Alpha-1 handling

The prompt requested Thymalin, but the verified catalog does not list it. CP-045 Thymosin Alpha-1 is present and can be used as an UPDATE link for thymic-peptide context, not as a substitute. That distinction should be preserved in the patch file. A future catalog update can add Thymalin if the product owner supplies SKU, mass, purity, and PDP text. Until then, this article should not create hidden product coverage.

The article should state the catalog gap in the manifest, not in sales copy. Production copy can simply focus on Epitalon, TB-500, NAD+, and a related link to CP-045. The quality manifest carries the human-review note so editors know why the title differs from the original working table.

COA review across three chemistry types

The shared release questions are: does the lot match the SKU, does the molecular weight match the catalog, does HPLC-MS or another identity method confirm the main species, and do water and residual solvent lines support mass accounting? The differences are equally important. Epitalon needs short-peptide impurity review. TB-500 needs larger-peptide sequence and peak-shape review. NAD+ needs coenzyme identity and stability review.

Glossary links should include <a href="/glossary/lyophilizate">lyophilizate</a>, <a href="/glossary/molecular-weight">molecular weight</a>, <a href="/glossary/hplc-ms">HPLC-MS</a>, <a href="/glossary/oxidation">oxidation</a>, and <a href="/glossary/certificate-of-analysis">Certificate of Analysis</a>. This creates a practical route from content to PDP to method language for Canada Peptides buyers in Toronto and across Canada.

Summary

The article should publish as an Epitalon, TB-500, and NAD+ reference-standard guide because those are the verified catalog-backed targets. Thymalin is a catalog gap and should not receive an invented SKU. CP-045 Thymosin Alpha-1 can be an adjacent update link, not a substitute.

This treatment closes coverage for CP-040, CP-031, and CP-041 while preserving scientific accuracy. It also teaches a broader quality lesson: category labels do not replace molecule-specific chemistry.

Release-file review checklist

For release-file review, keep the chemistry anchored to the verified SKU list: CP-040, CP-031, CP-041, CP-045. Confirm sequence or scaffold, molecular weight, HPLC-MS verified identity, counter-ion or modification state, water content, and residual-solvent method before copying the article into a production CMS. Canada Peptides should keep each inline product reference tied to the lower-case PDP route and should keep the article language limited to research reference standard selection, analytical characterisation, and procurement traceability. If a future catalog update changes a molecular weight, adds a salt form, or introduces a new related product, revise the cross-links and the patch file before publication rather than editing the claim in isolation.

Human review should decide whether Thymalin is a future product. No Thymalin SKU was present in the verified catalog used for this package.

Procurement traceability notes

A procurement reader should be able to move from this article to a PDP, from the PDP to a lot COA, and from the COA to a reproducible method record without guessing. That means names, SKU codes, molecular weights, and analytical terms must stay consistent across the article body, glossary, and reverse-index patch. The article should therefore be handled as a controlled content asset: update the reviewed date, check the DOI links, rerun the banned-phrase scan, and confirm the article still links to at least three product pages and two research-guide resources before publication.

Publication integration notes

This article is deliberately transparent about catalog boundaries. The prompt asked for Thymalin, but the verified local catalog does not contain that product. The production page does not need to dwell on the gap; the manifest and patch handle it. The article should instead rank for the verified materials: Epitalon tetrapeptide reference standard, TB-500 thymosin beta-4-class peptide, and NAD+ lyophilized coenzyme reference material. That gives the longevity category a useful hub without inventing an SKU.

The editorial risk is category overreach. Epitalon, TB-500, and NAD+ sit in the same storefront category, but they are not chemically similar. The article should keep the comparison at the quality-system level: identity, purity, water, residual solvents, lot number, storage, and catalog traceability. The molecule-specific sections then do the real teaching. CP-045 Thymosin Alpha-1 should remain an UPDATE link only. It can provide thymic-peptide context, but it is not a stand-in for the missing Thymalin line from the prompt.

CMS acceptance notes

Before this object is pasted into the production article array, verify that the slug is unique, the title stays under the search-result length target, the meta description remains in the 150-160 character band, and each internal link resolves to an existing route. Keep the relatedSKUs array uppercase because the article object is a data artifact, while inline PDP links should stay lower-case to match the current route style. This separation prevents a reader-facing URL change from corrupting the SKU key used by the reverse index.

The publication checklist should be mechanical. Parse the JS file, count body words before the references section, scan the body for blocked phrases, confirm at least five DOI-backed citations, count FAQ objects, count H2 headings, and count PDP and research-guide links. Then compare the article's SKU list with pdp_to_article_map_v3_patch.json. If the content and patch disagree, fix both in the same edit. That discipline matters more than adding another paragraph because these articles exist to repair internal linking while preserving catalog truth. The final editorial read should also compare the article card summary against the first body section. The two should support the same search intent, use the same verified SKU set, and avoid introducing a molecule or method that is absent from the saved patch file.

References

1. Malinin, V. V., & Khavinson, V. Kh. (2005). Effect of Epitalon on Telomerase Activity,Telomere Elongation and Proliferative Potential in Human Somatic Cells. Gerontological Aspects of Genome Peptide Regulation, 52–57. DOI: 10.1159/000085319 2. Yu, F. X., Lin, S. C., Morrison-Bogorad, M., Atkinson, M. A., & Yin, H. L. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. Journal of Biological Chemistry, 268(1), 502–509. DOI: 10.1016/s0021-9258(18)54179-x54179-x) 3. Sanders, M. C., Goldstein, A. L., & Wang, Y. L. (1992). Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences, 89(10), 4678–4682. DOI: 10.1073/pnas.89.10.4678 4. HANNAPPEL, E. (2007). β‐Thymosins. Annals of the New York Academy of Sciences, 1112(1), 21–37. DOI: 10.1196/annals.1415.018 5. Belenky, P., Bogan, K. L., & Brenner, C. (2007). NAD+ metabolism in health and disease. Trends in Biochemical Sciences, 32(1), 12–19. DOI: 10.1016/j.tibs.2006.11.006 6. Cantó, C., Menzies, Keir J., & Auwerx, J. (2015). NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metabolism, 22(1), 31–53. DOI: 10.1016/j.cmet.2015.05.023

Frequently asked questions

References

1. Malinin, V. V., & Khavinson, V. Kh. (2005). Effect of Epitalon on Telomerase Activity,Telomere Elongation and Proliferative Potential in Human Somatic Cells. Gerontological Aspects of Genome Peptide Regulation, 52–57. · link
2. Yu, F. X., Lin, S. C., Morrison-Bogorad, M., Atkinson, M. A., & Yin, H. L. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. Journal of Biological Chemistry, 268(1), 502–509. · link
3. Sanders, M. C., Goldstein, A. L., & Wang, Y. L. (1992). Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences, 89(10), 4678–4682. · link
4. HANNAPPEL, E. (2007). β‐Thymosins. Annals of the New York Academy of Sciences, 1112(1), 21–37. · link
5. Belenky, P., Bogan, K. L., & Brenner, C. (2007). NAD+ metabolism in health and disease. Trends in Biochemical Sciences, 32(1), 12–19. · link
6. Cantó, C., Menzies, Keir J., & Auwerx, J. (2015). NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metabolism, 22(1), 31–53. · link

References

1. Yu F., Lin S., Morrison-Bogorad M. et al. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins.. Journal of Biological Chemistry. · DOI
2. Low T., Goldstein A. (1982). Chemical characterization of thymosin beta 4.. Journal of Biological Chemistry. · DOI
3. Sikiric P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. · DOI
4. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
5. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
6. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI
7. Rauh M. (2012). LC–MS/MS for protein and peptide quantification in clinical chemistry. Journal of Chromatography B. · DOI
8. Manning M., Chou D., Murphy B. et al. (2010). Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. · DOI